<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug-induced lupus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug-induced lupus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drug-induced lupus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph F Merola, MD, MMSc, FAAD, FACR</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Certain drugs may trigger an autoimmune response; most often, these drugs induce autoantibodies, which may occur in a significant number of patients, but most of these patients do not develop signs of an autoantibody-associated disease. In some patients, a clinical syndrome with features similar to systemic lupus erythematosus (SLE) may develop, which is termed drug-induced lupus. As examples, <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> and anti-tumor necrosis factor (TNF) therapies often cause increased levels of antinuclear antibodies (ANAs) in serum, yet few patients with these antibodies develop clinical symptoms such as rash, serositis, or arthritis suggesting drug-induced disease [<a href="#rid1">1</a>].</p><p>Drug-induced lupus has similarities to spontaneous SLE, but there are some differences in clinical and immunologic features and in the frequency of such features. The clinical and serologic pattern of disease is also often drug-specific, and a single pattern is not seen across all agents. A subset of patients will have a clinical syndrome that is more consistent with drug-induced subacute cutaneous lupus erythematosus (SCLE). A few other types of drug-induced cutaneous lupus have also been described.</p><p>This topic will review causes, pathogenesis, clinical manifestations, diagnosis, and approach to management of drug-induced lupus. The clinical manifestations, diagnosis, and treatment of idiopathic SLE in adults and in children are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The demographic characteristics of drug-induced lupus largely depend upon the populations most likely to receive the relevant drugs. There are an estimated 15,000 to 30,000 cases of drug-induced lupus per year in the United States [<a href="#rid2">2</a>]. It is generally equally common in males and females, and more common in older adults and White populations [<a href="#rid2">2,3</a>]. An exception is minocycline-induced lupus, which is mostly observed in young women treated for acne.</p><p>The risk for developing drug-induced lupus varies substantially between different medications, ranging from 15 to 20 percent of those taking <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> and 7 to 13 percent of those taking <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, to as low as 2 per 1000 for those taking a tumor necrosis factor (TNF) inhibitor, and 5 per 10,000 of those taking <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> [<a href="#rid2">2</a>]. However, the relative incidence of drug-induced lupus from each of these agents will depend upon the extent to which they are prescribed.</p><p class="headingAnchor" id="H6"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H1519663580"><span class="h2">Mechanisms and risk factors</span><span class="headingEndMark"> — </span>The mechanism or mechanisms involved in drug-induced lupus remain uncertain. However, various theories have been developed regarding the pathogenesis of drug-induced lupus [<a href="#rid4">4</a>]. Inherited differences in drug metabolism (eg, acetylator status) and immunogenetic characteristics are genetic factors that may influence the risk of developing disease. Potential disease mechanisms include:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in oxidative drug metabolism</p><p class="bulletIndent1"><span class="glyph">●</span>Drugs acting as haptens or agonists for drug-specific T cells</p><p class="bulletIndent1"><span class="glyph">●</span>Cytotoxic drug metabolites causing pathology</p><p class="bulletIndent1"><span class="glyph">●</span>Drugs nonspecifically activating lymphocytes</p><p class="bulletIndent1"><span class="glyph">●</span>Drug metabolites disrupting central immune tolerance</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in thymus function</p><p class="bulletIndent1"><span class="glyph">●</span>Interference with cytotoxic T lymphocyte antigen 4 (CTLA-4) or programmed cell death receptor 1 (PD-1) immune checkpoint molecules [<a href="#rid5">5</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in innate immune responses, particularly neutrophilic responses such as engagement and formation of the "neutrophil extracellular trap" (NET) and exposure of autoantigens [<a href="#rid6">6</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Epigenetic mechanisms, with deoxyribonucleic acid (DNA) methylation changes in particular [<a href="#rid7">7</a>]</p><p></p><p>Multiple risk factors may be involved for a given agent. As an example, risk factors for hydralazine-induced lupus include drug dose (especially doses greater than 200 mg/day and/or a cumulative dose of more than 100 g), female sex, slow hepatic acetylation, and immunogenetic factors [<a href="#rid8">8-11</a>].</p><p>Regardless of the mechanism, the result has the hallmarks of autoimmunity, and the clinical manifestations result from immune-mediated effects upon the target organs. (See <a class="local">'Clinical spectrum of drug-induced lupus'</a> below.)</p><p class="headingAnchor" id="H1339498"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Although the pathogenesis of drug-induced lupus is not well understood, genetic predisposition may play a role. For certain drugs, genetically determined effects upon drug metabolism are clearly important. Immunogenetic characteristics and other factors may also play a role.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunogenetics</strong> – Possible genetic risk factors include human leukocyte antigen (HLA) DR4, HLA-DR0301, and the complement C4 null allele [<a href="#rid3">3,10-12</a>]. These factors vary between different agents. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunogenetic risk factors for procainamide-induced lupus, which occurs more readily in slow acetylators, may include HLA-DR6Y, but not -DR4 or -DR3 [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Risk factors for hydralazine-induced lupus include female sex, slow hepatic acetylation, the HLA-DR4 genotype, and the complement C4 null allele [<a href="#rid8">8-11</a>]. In one study, lupus developed in 19 percent of women taking 200 mg of <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> daily, compared with 13 of 13 women who also had the HLA-DR4 genotype [<a href="#rid10">10</a>]. These factors may interact; it is possible that slow acetylation increases free drug levels, while low levels of C4 might prevent clearance of any immune complexes that are formed [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with HLA-DQB1 and either HLA-DR2 or HLA-DR4 may be at increased risk of developing minocycline-induced lupus [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acetylator status</strong> – Drug-induced lupus is more likely to develop and develops sooner with certain drugs metabolized by acetylation in those patients who are slow acetylators, ie, those in whom there is a genetically mediated decrease in the hepatic synthesis of N-acetyltransferase [<a href="#rid15">15-17</a>]. Examples of such drugs include <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> and <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>. (See <a class="local">'Causative drugs'</a> below.)</p><p></p><p class="bulletIndent1">In contrast to the high degree of risk for drug-induced lupus with <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, particularly in slow acetylators, there is little or no antinuclear antibody (ANA) formation or symptomatic lupus following the administration of N-acetylprocainamide (NAPA), the major active metabolite of procainamide [<a href="#rid18">18</a>]; furthermore, remission of procainamide-induced lupus can be achieved by switching to NAPA [<a href="#rid19">19</a>]. These observations suggest an important pathogenetic role for the aromatic amino group on procainamide.</p><p></p><p class="bulletIndent1">By comparison, acetylation rate is not a risk factor for idiopathic lupus [<a href="#rid20">20</a>]. Acetylation rate also seems unlikely to be related to the etiopathogenesis of disease related to other agents such as <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and the tumor necrosis factor (TNF) inhibitors.</p><p></p><p class="headingAnchor" id="H11"><span class="h1">CAUSATIVE DRUGS</span><span class="headingEndMark"> — </span>Drugs associated with drug-induced lupus can generally be grouped in terms of their risk level or their probability of causing the disease.</p><p>The risk of drug-induced lupus varies across different medications. Drug-induced lupus-associated drugs have been classified as having a high (&gt;5 percent), moderate (1 to 5 percent), low (0.1 to 1 percent), or very low (approximately 0.1 percent) risk of inducing drug-induced lupus [<a href="#rid6">6,21,22</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk</strong> – Drugs that have been associated with the highest risk of inducing drug-induced lupus in an individual patient include <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> (15 to 20 percent incidence per year) [<a href="#rid2">2</a>] and <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> (5 to 10 percent incidence per year) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate risk</strong> – <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">Quinidine</a> has been associated with a moderate risk of drug-induced lupus [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk</strong> – Drugs thought to be associated with a low risk include <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a>, and <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> [<a href="#rid24">24-27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Very low risk</strong> – Drugs associated with very low risk include statins (<a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>, <a class="drug drug_general" data-topicid="8473" href="/z/d/drug information/8473.html" rel="external">fluvastatin</a>, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>) [<a href="#rid28">28-30</a>] and tumor necrosis factor (TNF) inhibitors (<a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>, certolizumab) [<a href="#rid31">31-35</a>], as well as a variety of other miscellaneous drugs (isopropamide, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>, <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a>, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>, <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>, <a class="drug drug_general" data-topicid="9774" href="/z/d/drug information/9774.html" rel="external">pindolol</a>, <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">prazosin</a>, <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> carbonate, <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a>, <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>, <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">ethosuximide</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>, trimethadione, phenylbutazone, <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">chlorthalidone</a>, aminoglutethimide, levodopa, ophthalmic <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a>, interferon alfa, and interleukin [IL] 2) [<a href="#rid6">6</a>].</p><p></p><p>Cases of possible drug-induced lupus secondary to <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a>/sulfamethoxazole have also been reported [<a href="#rid36">36,37</a>]. Rarely, cancer immunotherapy agents such as <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> have been associated with systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus (SCLE), and lupus-like cutaneous reactions [<a href="#rid31">31,38,39</a>]. A more detailed discussion of rheumatologic complications of immune checkpoint inhibitors can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/114506.html" rel="external">"Rheumatologic complications of checkpoint inhibitor immunotherapy"</a>.)</p><p>These drugs and others have also been classified in terms of probability of causing drug-induced lupus [<a href="#rid6">6,15,16,21,40-44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definite</strong> – Medications identified as definitely causing drug-induced lupus include <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, anti-TNF therapy (most commonly with <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>), interferon alfa, <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>, <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, and practolol [<a href="#rid42">42,45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probable</strong> – Medications identified as probable causes of drug-induced lupus include anticonvulsants (<a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, mephenytoin, trimethadione, <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">ethosuximide</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>), antithyroid drugs, antimicrobial agents (sulfonamides, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> [<a href="#rid47">47</a>], <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>), beta blockers, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, paraaminosalicylate, <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a>, interferon gamma, <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a>, <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a>, and <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid45">45,47-52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible</strong> – Medications that are possible causes of drug-induced lupus include gold salts, penicillin, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, statins (eg, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a>, <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, and <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">atorvastatin</a>), <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a>, <a class="drug drug_general" data-topicid="8488" href="/z/d/drug information/8488.html" rel="external">gemfibrozil</a>, valproate, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, ophthalmic <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a>, and 5-aminosalicylate.</p><p></p><p>The drugs most likely to cause drug-induced SCLE differ from those most likely to cause typical drug-induced lupus and are discussed below. (See <a class="local">'Subacute cutaneous lupus erythematosus'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h1">CLINICAL SPECTRUM OF DRUG-INDUCED LUPUS</span><span class="headingEndMark"> — </span>Drug-induced lupus refers to a spectrum of drug-induced reactions similar to that of idiopathic systemic lupus erythematosus (SLE), but typically without the major organ-threatening complications. A subset of patients will have a clinical syndrome that is more consistent with drug-induced subacute cutaneous lupus erythematosus (SCLE). A few other types of drug-induced cutaneous lupus have also been described. Different drugs are associated with different clinical and serologic profiles for both drug-induced lupus and drug-induced SCLE.</p><p class="headingAnchor" id="H3404030"><span class="h2">Drug-induced lupus</span><span class="headingEndMark"> — </span>Drug-induced lupus includes a spectrum of reactions characterized most commonly by a phenotype similar to that of idiopathic SLE, but usually without the major organ-threatening complications  (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H390931809"><span class="h3">Clinical presentation</span><span class="headingEndMark"> — </span>The most common symptoms of drug-induced lupus include fever, arthralgias/arthritis, myalgias, rash, and/or serositis. More severe manifestations, such as kidney disease and central nervous system involvement, are uncommon [<a href="#rid2">2,15</a>], although they may occur [<a href="#rid11">11,53,54</a>]. Certain drugs may be associated with different clinical and serologic profiles  (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 1</a>). As an example, pleuritis occurs in approximately half of the procainamide-induced lupus patients, 22 percent of those with quinidine-induced disease, and less than 1 percent of those with <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> [<a href="#rid2">2</a>]. (See <a class="local">'Drug-specific clinical profiles'</a> below.)</p><p>Cutaneous manifestations are much less common in drug-induced lupus compared with idiopathic SLE, although SCLE is often drug-induced. Drug-induced discoid lupus has also been reported but appears rare [<a href="#rid55">55,56</a>]. (See <a class="local">'Subacute cutaneous lupus erythematosus'</a> below and <a class="local">'Other types of drug-induced cutaneous lupus'</a> below.)</p><p>Symptom onset generally develops after months to years of exposure, although onset may also be abrupt. Both <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> and <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> have been reported as being associated with drug-induced lupus even &gt;3 years after initiating treatment with the drug [<a href="#rid57">57</a>].</p><p>Characteristic laboratory findings and autoantibodies are discussed further below. (See <a class="local">'Laboratory tests and characteristic autoantibodies'</a> below.)</p><p class="headingAnchor" id="H3499206103"><span class="h3">Drug-specific clinical profiles</span><span class="headingEndMark"> — </span>The pattern of drug-induced lupus clinical profiles and serologies is largely drug-specific and may deviate from what has been taught based upon classical presentations of procainamide-induced and hydralazine-induced disease. The following examples illustrate the spectrum of clinical and laboratory findings that may occur with different agents implicated as causes of drug-induced lupus  (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procainamide</strong> – <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">Procainamide</a> may be the most common cause of drug-induced lupus, which may be mediated by the reactive metabolite procainamide hydroxylamine. A positive antinuclear antibody (ANA) occurs in almost all patients given the drug for more than two years [<a href="#rid8">8</a>]; ANAs are more likely to develop and to develop earlier in slow acetylators [<a href="#rid58">58</a>]. Symptoms, however, develop in approximately one-third of those who have taken procainamide for more than one year [<a href="#rid8">8</a>]; the determining factors for susceptibility to symptomatic disease are not known [<a href="#rid58">58,59</a>]. Serositis typically occurs with procainamide and usually consists of pleuritis, with or without lung infiltrates, and is sometimes accompanied by pericarditis [<a href="#rid60">60</a>]. Antihistone antibodies are typically present in drug-induced lupus due to procainamide.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydralazine</strong> – Clinical disease occurs in approximately 5 to 10 percent of patients receiving <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> [<a href="#rid15">15,59</a>]. Even low doses may not be safe, as clinical disease can develop in up to 5 percent of slow acetylators taking 100 mg/day [<a href="#rid61">61</a>]. Symptom onset may develop years later. The skin is involved in up to one-third of patients with drug-induced reactions due to hydralazine [<a href="#rid57">57</a>]. Hydralazine use can also be associated with an antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis involving the kidney, which is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minocycline</strong> – <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a>, unlike other tetracyclines, appears to cause a drug-induced lupus syndrome, particularly among young women being treated for acne [<a href="#rid24">24,44,62-64</a>]. The risk of developing drug-induced lupus from minocycline use is relatively low (hazard ratio 2.6 to 3.1), and the absolute risk is only approximately 1 in 1000 patients exposed [<a href="#rid65">65</a>]. Features of minocycline-induced lupus include arthralgia (73 to 100 percent), arthritis (12 to 45 percent), fever (38 percent), and rash (29 percent) [<a href="#rid24">24</a>]. Other clinical features that have been described are morning stiffness, myalgia, pneumonitis, and cutaneous vasculitis [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">Laboratory evidence of liver involvement may be seen in 32 to 54 percent of patients with drug-induced disease [<a href="#rid66">66</a>].The autoantibody pattern differs from most other forms of drug-induced lupus. A positive ANA (including anti-double-stranded DNA [anti-dsDNA] antibodies) and perinuclear ANCA (P-ANCA) test has been found in 92 and 83 percent of tested sera, respectively; by comparison, antihistone antibodies are uncommon (0 to 13 percent) [<a href="#rid66">66</a>]. Most cases of minocycline-induced lupus resolve within a relatively short time after drug discontinuation; young children may be at increased risk for prolonged disease following <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> exposure [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1">Unlike with most other agents that may cause drug-induced lupus, the author prefers to avoid use of <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> in patients with established (idiopathic) SLE. (See <a class="local">'Implications for patients with idiopathic systemic lupus erythematosus'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TNF inhibitors</strong> – Most cases of drug-induced lupus associated with the use of a tumor necrosis factor (TNF) inhibitor are characterized by skin and pleuropericardial abnormalities, along with the formation of autoantibodies such as those to dsDNA, Sm antigen, or histones. TNF inhibitor therapy with <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> has been associated with the development of positive test results for ANAs (13 to 83 percent) and anti-dsDNA antibodies (3 to 32 percent) [<a href="#rid43">43,68-70</a>]. Such antibodies have also been reported in patients receiving <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a> and <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a>. In contrast to findings with other medications, antihistone antibodies are usually absent. Hypocomplementemia is occasionally observed [<a href="#rid71">71</a>]. The skin is involved in over 80 percent of cases induced by TNF inhibitors [<a href="#rid34">34</a>]. Renal and neurologic manifestations are extremely rare. (See  <a class="medical medical_review" href="/z/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases", section on 'Systemic lupus erythematosus'</a>.)</p><p></p><p class="bulletIndent1">The proportion of patients who develop the de novo production of ANA or anti-dsDNA antibodies largely exceeds that of patients who develop drug-induced lupus; thus, the development of such antibodies should not be viewed as a sign of impending drug-induced lupus. As mentioned above, the frequency of drug-induced lupus is well below 1 percent (see <a class="local">'Causative drugs'</a> above). The high association with ANA formation often drives confusion among clinicians, resulting in withholding potentially effective therapies for patients. Anti-dsDNA antibodies induced by TNF inhibitors appear to be of predominantly immunoglobulin (Ig) M class, in contrast to primary SLE autoantibodies being predominantly of the IgG isotype [<a href="#rid33">33,72</a>]. It has been hypothesized that this may be associated with less pathogenic sequelae.</p><p></p><p class="bulletIndent1">In most affected patients, drug-induced lupus associated with TNF inhibitor use resolves completely upon discontinuation of the TNF inhibitor. As an example, a case series of four patients who developed definite or probable drug-induced lupus while receiving <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> had resolution of symptoms within two to six weeks of discontinuing therapy [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Subacute cutaneous lupus erythematosus</span><span class="headingEndMark"> — </span>SCLE is drug-induced in a substantial proportion of patients who present with what is initially thought to be idiopathic SCLE and is distinct from the typical drug-induced lupus [<a href="#rid73">73</a>]. In one population-based case-control study involving 234 patients with SCLE, the condition appeared to be drug-induced in over one-third of patients [<a href="#rid32">32</a>]. The majority of patients with drug-induced SCLE (70 to 90 percent) were anti-Ro/SSA positive [<a href="#rid32">32</a>]. Drug-induced SCLE typically presents as an annular or psoriasiform, photodistributed cutaneous eruption. Additional information regarding drug-induced SCLE can be found separately. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Drug-induced subacute cutaneous lupus erythematosus'</a>.)</p><p>The drugs most likely to induce SCLE include <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> [<a href="#rid74">74</a>], calcium channel blockers (eg, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>), and angiotensin-converting enzyme inhibitors [<a href="#rid75">75</a>]. Drugs such as statins, TNF inhibitors, and proton-pump inhibitors are also associated with drug-induced SCLE [<a href="#rid76">76-79</a>].</p><p>Additional reports suggest the following agents may also cause the syndrome: <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="9233" href="/z/d/drug information/9233.html" rel="external">acebutolol</a>, various agents used to treat malignancies (<a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, uracil-tegafur, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a>, <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a>, <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>, <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">palbociclib</a> [<a href="#rid80">80</a>]), <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, and the antifungal agent <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">terbinafine</a> [<a href="#rid2">2,3,6,32,49,81-84</a>]. New onset or exacerbation of preexisting SCLE was noted after exposure to terbinafine in five patients [<a href="#rid49">49</a>]. SCLE has been associated with interferon alfa therapy in a case report [<a href="#rid85">85</a>]. <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">Nivolumab</a>, a cancer immunotherapy agent, has also been described as causing SCLE [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H1538623488"><span class="h2">Other types of drug-induced cutaneous lupus</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced</strong> <strong>chronic cutaneous lupus erythematosus</strong> – Chronic cutaneous drug-induced lupus is rare (including drug-induced discoid lupus) [<a href="#rid55">55,56</a>]. Reports have included association with tegafur, <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> compounds, and TNF inhibitors [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other lupus-like cutaneous reactions</strong> – Lupus-like cutaneous reactions (in addition to SCLE) have been reported with cancer immunotherapy agents such as <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid86">86,88,89</a>]. Drug-induced lupus tumidus has also been reported in association with TNF inhibitors and other drugs [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H25754200"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H3378261740"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The diagnostic evaluation of patients with suspected drug-induced lupus should be similar to that performed in patients suspected of idiopathic systemic lupus erythematosus (SLE). (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H2644680574"><span class="h3">History and physical examination</span><span class="headingEndMark"> — </span>The history and physical examination is the same as that for SLE, with particular attention to the following symptoms and signs (see  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'History and physical examination'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to medications associated with drug-induced lupus (see <a class="local">'Causative drugs'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Constitutional symptoms such as low-grade fever, anorexia, weight loss, fatigue</p><p class="bulletIndent1"><span class="glyph">●</span>Musculoskeletal symptoms (arthralgias and/or arthritis, myalgia)</p><p class="bulletIndent1"><span class="glyph">●</span>Chest pain suggestive pericarditis</p><p class="bulletIndent1"><span class="glyph">●</span>Skin lesions</p><p></p><p class="headingAnchor" id="H2987036860"><span class="h3">Laboratory tests and characteristic autoantibodies</span><span class="headingEndMark"> — </span>Laboratory testing should include the following routine laboratory tests and antibody tests:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count and differential</p><p class="bulletIndent1"><span class="glyph">●</span>Complete metabolic panel</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis with urine sediment</p><p class="bulletIndent1"><span class="glyph">●</span>Antinuclear antibody (ANA; ideally by indirect immunofluorescence testing)</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-double-stranded DNA (anti-dsDNA) antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Antihistone antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-Sm antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-Ro/SSA and anti-La/SSB antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-U1 ribonucleoprotein (RNP) antibodies</p><p></p><p>Antineutrophil cytoplasmic antibody (ANCA) should be obtained in patients who have been treated with <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a>, or <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">methimazole</a> [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p>Hematologic abnormalities commonly seen in idiopathic SLE such as leukopenia and thrombocytopenia are rare in drug-induced lupus. Hypocomplementemia is also uncommon in drug-induced lupus [<a href="#rid10">10</a>], except for quinidine-induced forms, in which low C3 and/or C4 levels have been described in up to one-third of cases [<a href="#rid23">23</a>]. Liver function abnormalities may occur and have been noted in 32 to 54 percent of patients with minocycline-induced lupus [<a href="#rid2">2</a>].</p><p>An important immunologic characteristic of drug-induced lupus is the presence of autoantibodies. The autoantibodies or patterns of autoantibodies that are seen largely depend upon the inciting agent  (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antihistone antibodies</strong> – Antihistone antibodies are present in more than 95 percent of patients overall, among those taking <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, and <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>; however, antihistone antibodies have been found in a smaller proportion of patients with drug-induced lupus associated with other medications, including <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a>, and statins (32, 42, and &lt;50 percent, respectively) [<a href="#rid91">91,92</a>]. Importantly, antihistone antibodies are also seen in up to 80 percent of patients with idiopathic SLE [<a href="#rid91">91,92</a>]; however, patients with idiopathic SLE also form a variety of other autoantibodies, including those directed against DNA and small RNPs, which are less common in drug-induced lupus.</p><p></p><p class="bulletIndent1">The antihistone antibodies in drug-induced lupus are primarily formed against a complex of the histone dimer H2A-H2B and DNA [<a href="#rid40">40,58,59</a>] and, with <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, to the H1 and H3-H4 complex [<a href="#rid91">91</a>]. DNA is required either to stabilize the complex or perhaps to contribute part of the antigenic epitope [<a href="#rid40">40</a>]. Although the drugs that can cause drug-induced lupus are markedly heterogeneous, there may be a common pathway for disease induction since the antihistone antibodies produced in patients receiving <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, hydralazine, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9233" href="/z/d/drug information/9233.html" rel="external">acebutolol</a>, <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, and <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a> are nearly identical in most [<a href="#rid40">40</a>], but not all, patients [<a href="#rid59">59</a>]. By contrast, the antihistone antibodies in idiopathic SLE are primarily directed against the H1 and H2B histone subunits [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1">The development of IgG antibodies to the complex of H2A-H2B and DNA soon after starting <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> is associated with a high risk of developing drug-induced lupus; by comparison, autoantibodies to single-stranded DNA or to histones alone do not distinguish between symptomatic or asymptomatic individuals [<a href="#rid93">93</a>]. It is not known if these observations apply to other causes of drug-induced lupus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-dsDNA antibodies</strong> – Anti-double-stranded DNA (anti-dsDNA) antibodies are typically absent in drug-induced lupus due to <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, and <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, but these antibodies are associated with drug-induced disease with other agents, particularly with interferon alfa and anti-tumor necrosis factor (TNF) agents. With the latter class of anticytokine therapies, although the majority of patients may eventually develop ANAs and other autoantibodies, including anti-dsDNA antibodies, relatively few patients with any of these antibodies develop clinical manifestations of drug-induced lupus [<a href="#rid94">94,95</a>]. (See <a class="local">'Drug-induced lupus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-Ro/SSA antibodies</strong> – The vast majority of patients (greater than 80 percent) with drug-induced subacute cutaneous lupus erythematosus (SCLE) have anti-Ro/SSA antibodies [<a href="#rid96">96</a>]. While not specific for drug-induced SCLE and seen in the context of other systemic autoimmune diseases, the presence of this antibody is expected in drug-induced SCLE presentations, and its absence should bring the diagnosis into question. Resolution of anti-Ro/SSA antibodies is also often observed after drug withdrawal in patients with drug-induced SCLE [<a href="#rid82">82,97</a>]. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus"</a> and  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Subacute cutaneous lupus erythematosus'</a>.)</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>There are no definitive tests or criteria for the diagnosis of drug-induced lupus; however, the diagnosis of drug-induced lupus is likely in the presence of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A history of taking one or more of the drugs known to be associated with this condition for at least one month, and often much longer (see <a class="local">'Causative drugs'</a> above), with the development of at least one clinical feature characteristic of SLE (see <a class="local">'Drug-induced lupus'</a> above). Patients typically exhibit some combination of arthralgia, myalgia, malaise, fever, serositis, and/or rash, but the diagnosis of drug-induced lupus does not require that a sufficient number of manifestations be exhibited to satisfy criteria for idiopathic SLE [<a href="#rid15">15,98,99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A positive test for ANAs. Antihistone antibodies are strongly associated with some forms of drug-induced lupus but are also present in patients with idiopathic SLE. Anti-dsDNA antibodies are not found in most forms of drug-induced lupus. (See <a class="local">'Laboratory tests and characteristic autoantibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of the clinical manifestations of the disease, typically within several weeks but sometimes up to several months after the offending drug has been discontinued [<a href="#rid99">99</a>]. The ANAs often persist for a greater duration than the symptoms and physical findings, and in most patients, autoantibodies persist indefinitely.</p><p></p><p>The diagnosis of drug-induced SCLE can be made in patients with clinical findings characteristic of idiopathic SCLE that have developed in association with exposure to a medication known to cause this disorder, typically one to five months after initiating therapy, in whom the cutaneous changes and other associated findings resolve after discontinuation of the suspected offending agent. The presence of more widespread involvement than is typical of idiopathic SCLE should heighten suspicion of drug-induced SCLE. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Subacute cutaneous lupus erythematosus'</a>.)</p><p class="headingAnchor" id="H21622846"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of drug-induced lupus is broad; it includes the idiopathic (ie, spontaneous) forms of both SLE and SCLE and depends further upon the clinical manifestations that are present. It is thus highly similar to the differential diagnosis in patients suspected of idiopathic SLE as well as that of SCLE, which also includes other skin disorders with an annular or psoriasiform/papulosquamous morphology as well as a number of photodistributed dermatoses. Also included in the differential diagnosis is drug-induced ANCA vasculitis depending on the specific drug involved.</p><p>These differential diagnoses of SLE and SCLE are discussed in detail separately; however, we present some of the key features differentiating drug-induced lupus from the idiopathic diseases, as well as from drug-induced ANCA vasculitis, below. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Acute cutaneous lupus erythematosus'</a> and  <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic SLE</strong> – The differentiation from idiopathic systemic lupus erythematosus (SLE) may sometimes be difficult because of the number of different agents that can cause a positive ANA and may cause drug-induced lupus; and the frequent occurrence of arthralgia or arthritis, fever, and serositis with a positive ANA in both disorders. Features more suggestive of idiopathic SLE, and which are much less common in drug-induced lupus, include renal, neurologic, cutaneous, and severe hematologic involvement. Antihistone antibodies may be seen in both idiopathic and drug-induced lupus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic SCLE</strong> – Several features are much more common in drug-induced than idiopathic subacute cutaneous lupus erythematosus (SCLE), although the clinical findings are not unique [<a href="#rid97">97</a>]. The cutaneous eruption in patients with drug-induced SCLE is frequently widespread in its distribution, which is uncommon in idiopathic SCLE. It is more likely to have bullous features and a vasculitic component. Additionally, anti-Ro/SSA antibodies are present in a high proportion of patients, but will disappear after resolution of the skin disease in approximately three-quarters of the patients<strong> </strong>in whom they are present. The presence of eosinophils on histopathology of the skin of SCLE does not appear to distinguish drug-induced from idiopathic forms [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced ANCA vasculitis</strong> – Drug-induced antineutrophil cytoplasmic antibody (ANCA) vasculitis can also be associated with some of the same drugs known to cause drug-induced lupus, which include <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, and <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a>. In contrast to more typical drug-induced lupus, patients with hydralazine-induced vasculitis may have more severe kidney involvement and require cytotoxic or other immunosuppressive therapy as in other ANCA-positive vasculitides. Renal disease in drug-induced lupus is rare and usually due to a necrotizing glomerulonephritis with little or no immune complex deposition [<a href="#rid54">54,101,102</a>], although an immune complex-mediated glomerulonephritis can occur [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Drug-induced ANCA-associated vasculitis'</a>.)</p><p></p><p class="bulletIndent1">ANCA positivity can also be observed in idiopathic SLE in approximately 15 to 20 percent of patients, and occasionally in other systemic rheumatic diseases [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Nonvasculitic systemic rheumatic diseases'</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1074089878"><span class="h2">Discontinuation of offending medication</span><span class="headingEndMark"> — </span>The initial step in management is to discontinue the offending medication. Drug-induced lupus typically resolves after discontinuation of the medication, but complete resolution may require weeks to months. Factors influencing the time to resolution include the type of drug, the extent of clinical manifestations, and patient characteristics [<a href="#rid6">6</a>]. Some experts suggest that lack of resolution of symptoms suggests the presence of preexisting systemic lupus erythematosus (SLE) that was unmasked by the medication.</p><p class="headingAnchor" id="H3271797727"><span class="h2">Medical management in selected cases</span><span class="headingEndMark"> — </span>Specific manifestations of drug-induced systemic or cutaneous lupus may be treated temporarily until they resolve using the same approaches as those used in patients with idiopathic SLE and subacute cutaneous lupus erythematosus (SCLE). There are no randomized trials that have examined the optimal treatment approach to drug-induced lupus, and the management is based upon the observational data and the experience of the authors and other experts that medications that are effective in idiopathic SLE and SCLE are also effective in patients with drug-induced illness [<a href="#rid2">2,92,104</a>], and that symptoms gradually resolve after drug discontinuation in most patients. The duration of treatment is guided by the clinical response, and the decision to discontinue or taper therapy is based on clinical improvement after cessation of the offending agent over weeks to months.</p><p>Examples of treatment approaches for drug-induced lupus include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Arthralgia and arthritis may be treated with nonsteroidal antiinflammatory drugs (NSAIDs). (See  <a class="medical medical_review" href="/z/d/html/4673.html" rel="external">"Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus", section on 'Treatment of arthritis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> can be used temporarily if constitutional, cutaneous, and musculoskeletal symptoms do not clear within four to eight weeks. (See  <a class="medical medical_review" href="/z/d/html/4673.html" rel="external">"Arthritis and other musculoskeletal manifestations of systemic lupus erythematosus", section on 'Treatment of arthritis'</a> and  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Treatment of specific SLE manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic glucocorticoids are infrequently required; however, they may be of benefit if used temporarily for patients with more severe pleurisy or pericarditis, for which they can usually induce quick resolution. (See  <a class="medical medical_review" href="/z/d/html/4680.html" rel="external">"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults", section on 'Course and treatment'</a> and  <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">"Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous lesions from drug-induced SCLE typically respond to topical therapies such as topical corticosteroids. (See  <a class="medical medical_review" href="/z/d/html/13772.html" rel="external">"Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus", section on 'Overview'</a>.)</p><p></p><p>The evolution of the autoantibody profile should not be used as a guide to tailor therapy, since autoantibody titers typically remain positive long after the clinical remission of drug-induced lupus. (See  <a class="medical medical_review" href="/z/d/html/13772.html" rel="external">"Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus"</a> and  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Approach to drug therapy'</a>.)</p><p>We do not rechallenge patients with a medication that has been identified as a likely cause of drug-induced lupus in that individual.</p><p class="headingAnchor" id="H21622825"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H327572073"><span class="h2">Outcomes</span><span class="headingEndMark"> — </span>The prognosis of drug-induced lupus is generally quite favorable in most case series and in our experience, with disease typically resolving after drug withdrawal, even though management of specific manifestations (eg, with nonsteroidal antiinflammatory drugs [NSAIDs] or <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>) may be needed for up to several months in some patients [<a href="#rid2">2,92,104</a>]. Occasional patients require glucocorticoid therapy, but life-threatening disease is infrequent and may suggest idiopathic systemic lupus erythematosus (SLE)-like presentation [<a href="#rid3">3</a>]. (See <a class="local">'Management'</a> above.)</p><p class="headingAnchor" id="H4249350403"><span class="h2">Implications for patients with idiopathic systemic lupus erythematosus</span><span class="headingEndMark"> — </span>The safe use of drugs associated with drug-induced lupus in the patient with idiopathic SLE remains unclear, and there is little evidence to support the avoidance of these medications in the setting of SLE. The increasing use of tumor necrosis factor (TNF) inhibitors may offer some relevant insight into this dilemma. TNF inhibitor use is associated with a high rate of antinuclear antibody (ANA) induction, including anti-double-stranded DNA (dsDNA) antibody production, with reports of a positive ANA in greater than 50 percent of patients with prolonged exposure to anti-TNF therapy [<a href="#rid105">105</a>]. Despite this high rate of antibody induction, most are of the IgM subclass (seemingly less pathogenic), and clinical manifestations are rare and/or mild when they occur. Transient autoantibody formation in the setting of medication use does not seem to correlate with SLE flares acutely [<a href="#rid106">106</a>]. Rare lupus nephritis has been reported in the setting of anti-TNF use.</p><p>A conservative approach to the SLE patient receiving any medications previously reported to cause drug-induced lupus is to observe for clinical evidence of increased disease activity, including novel organ manifestations, as well as with appropriate laboratory monitoring (see  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Laboratory evaluation'</a>). More data are needed to compare the safety of short-term medication exposure in this group with longer-term exposure risk.</p><p class="headingAnchor" id="H3800636521"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110740.html" rel="external">"Society guideline links: Systemic lupus erythematosus"</a>.)</p><p class="headingAnchor" id="H21622809"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and epidemiology</strong> – Certain drugs may trigger an autoimmune response, which in some patients may result in a clinical syndrome with features similar to systemic or cutaneous lupus erythematosus, termed drug-induced lupus. Most commonly, these drugs induce autoantibodies without causing a clinical disorder. Drug-induced lupus has similarities to spontaneous (idiopathic) systemic lupus erythematosus (SLE), but there are some differences in clinical and immunologic features and in the frequency of such features  (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causative drugs</strong> – Drugs associated with drug-induced lupus can generally be grouped in terms of their risk level or their probability of causing the disease. The drugs associated with the highest risk of inducing lupus in an individual patient are <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, and <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>. Other medications identified as definitely causing drug-induced lupus include <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, tumor necrosis factor (TNF) inhibitors, interferon alfa, <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>, <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, and practolol. A variety of agents have been implicated as probable or possible, but not definite, causes of drug-induced lupus, including anticonvulsants, antithyroid drugs, antimicrobials, and others. (See <a class="local">'Causative drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical spectrum</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drug-induced lupus</strong> – The most common manifestations include fever, myalgias, arthralgias, arthritis, and serositis. The frequency of these manifestations vary with the drug. Hematologic abnormalities and more severe manifestations, such as kidney disease and central nervous system involvement, are uncommon, although they can occur. Liver function abnormalities have been noted, especially in patients with minocycline-induced lupus. Cutaneous manifestations are much less common in drug-induced (systemic) lupus compared with idiopathic SLE, although subacute cutaneous lupus erythematosus (SCLE) is often drug-induced. (See <a class="local">'Drug-induced lupus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subacute cutaneous lupus erythematosus</strong> – SCLE may be drug-induced in a substantial proportion of patients, and drug-induced SCLE is distinct from the typical drug-induced lupus syndrome. The majority of patients with drug-induced SCLE are anti-Ro/SSA-positive. Drug-induced SCLE typically presents as an annular or psoriasiform, photodistributed cutaneous eruption. Medications most often associated with SCLE include <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a>, calcium channel blockers, angiotensin-converting enzyme inhibitors, statins, TNF inhibitors, and proton-pump inhibitors. (See <a class="local">'Subacute cutaneous lupus erythematosus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect drug-induced lupus</strong> – Drug-induced lupus should be suspected when a patient taking one or more of the suspect drugs for at least one month, and usually much longer, presents with some combination of arthralgias/arthritis, myalgia, malaise, fever, rash, and/or serositis. At least one feature typical of SLE should be present, but patients with drug-induced lupus often do not exhibit a sufficient number of manifestations to satisfy criteria for idiopathic SLE. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The diagnostic evaluation of patients with suspected drug-induced lupus should be similar to that performed in patients suspected of idiopathic SLE. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History and physical examination</strong> – The history and physical examination should include attention to exposure to medications associated with drug-induced lupus; constitutional symptoms (eg, low grade fever, weight loss, fatigue); arthralgias/arthritis or myalgia; chest pain suggestive of pericarditis; skin lesions. (See <a class="local">'History and physical examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory tests and characteristic autoantibodies</strong> – The autoantibodies or patterns of autoantibodies that are seen largely depend upon the inciting agent, but for certain drugs may include antinuclear antibodies (ANAs) that have specificity for histone proteins, while with disease due to other drugs, antibodies that are more often associated with idiopathic SLE (eg, anti-double stranded [anti-dsDNA] antibodies) or with systemic vasculitis (eg, antineutrophil cytoplasmic antibodies [ANCAs]) may be present  (<a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">table 1</a>). (See <a class="local">'Laboratory tests and characteristic autoantibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – There are no definitive tests or criteria for the diagnosis of drug-induced lupus; however, the diagnosis of drug-induced lupus is likely in the presence of the following (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A history of taking one or more of the drugs known to be associated with this condition for at least one month, and often much longer, with the development of at least one clinical feature characteristic of SLE. Patients typically exhibit some combination of arthralgia, myalgia, malaise, fever, serositis, and/or rash.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A positive test for ANAs. Antihistone antibodies are strongly associated with some forms of drug-induced lupus but are also present in patients with idiopathic SLE. Anti-dsDNA antibodies are not found in most forms of drug-induced lupus.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Resolution of the clinical manifestations of the disease, typically within several weeks but sometimes up to several months after the offending drug has been discontinued. The ANAs often persist for a greater duration than the symptoms and physical findings, and in most patients, autoantibodies persist indefinitely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The initial management of drug-induced systemic or cutaneous lupus requires discontinuation of the offending medication. Drug-induced lupus typically resolves after discontinuation, but complete resolution may require weeks to months. Specific manifestations of drug-induced systemic or cutaneous lupus may be treated temporarily until they resolve using the same approaches as those used in patients with idiopathic SLE and SCLE. (See <a class="local">'Medical management in selected cases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The prognosis is generally quite favorable, with disease typically resolving after drug withdrawal, even though treatment may be needed for up to several months in some patients. (See <a class="local">'Outcomes'</a> above.)</p><p></p><p class="headingAnchor" id="H359552195"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter Schur, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Olsen NJ. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 2004; 18:677.</a></li><li><a class="nounderline abstract_t">Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108:166.</a></li><li><a class="nounderline abstract_t">Vasoo S. Drug-induced lupus: an update. Lupus 2006; 15:757.</a></li><li><a class="nounderline abstract_t">Rubin RL. Drug-induced lupus. Toxicology 2005; 209:135.</a></li><li><a class="nounderline abstract_t">Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. Curr Drug Saf 2018; 13:150.</a></li><li><a class="nounderline abstract_t">Vaglio A, Grayson PC, Fenaroli P, et al. Drug-induced lupus: Traditional and new concepts. Autoimmun Rev 2018; 17:912.</a></li><li><a class="nounderline abstract_t">Javierre BM, Richardson B. A new epigenetic challenge: systemic lupus erythematosus. Adv Exp Med Biol 2011; 711:117.</a></li><li><a class="nounderline abstract_t">Yung R, Richardson B. Drug-induced rheumatic syndromes. Bull Rheum Dis 2002; 51:1.</a></li><li><a class="nounderline abstract_t">Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed) 1984; 289:410.</a></li><li><a class="nounderline abstract_t">Batchelor JR, Welsh KI, Tinoco RM, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980; 1:1107.</a></li><li><a class="nounderline abstract_t">Speirs C, Fielder AH, Chapel H, et al. Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet 1989; 1:922.</a></li><li><a class="nounderline abstract_t">Gunnarsson I, Nordmark B, Hassan Bakri A, et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford) 2000; 39:886.</a></li><li><a class="nounderline abstract_t">Adams LE, Mongey AB. Role of genetic factors in drug-related autoimmunity. Lupus 1994; 3:443.</a></li><li><a class="nounderline abstract_t">Dunphy J, Oliver M, Rands AL, et al. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 2000; 142:461.</a></li><li><a class="nounderline abstract_t">Hess E. Drug-related lupus. N Engl J Med 1988; 318:1460.</a></li><li><a class="nounderline abstract_t">Fritzler MJ. Drugs recently associated with lupus syndromes. Lupus 1994; 3:455.</a></li><li><a class="nounderline abstract_t">Grant DM, Mörike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990; 85:968.</a></li><li><a class="nounderline abstract_t">Reidenberg MM, Drayer DE. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus. Angiology 1986; 37:968.</a></li><li><a class="nounderline abstract_t">Stec GP, Lertora JJ, Atkinson AJ Jr, et al. Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy. Ann Intern Med 1979; 90:799.</a></li><li><a class="nounderline abstract_t">Reidenberg MM, Drayer DE, Lorenzo B, et al. Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum 1993; 36:971.</a></li><li><a class="nounderline abstract_t">Arnaud L, Mertz P, Gavand PE, et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis 2019; 78:504.</a></li><li><a class="nounderline abstract_t">Araújo-Fernández S, Ahijón-Lana M, Isenberg DA. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. Lupus 2014; 23:545.</a></li><li><a class="nounderline abstract_t">Alloway JA, Salata MP. Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum 1995; 24:315.</a></li><li><a class="nounderline abstract_t">Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999; 159:493.</a></li><li><a class="nounderline abstract_t">Schoonen WM, Thomas SL, Somers EC, et al. Do selected drugs increase the risk of lupus? A matched case-control study. Br J Clin Pharmacol 2010; 70:588.</a></li><li><a class="nounderline abstract_t">Rothfield NF, Bierer WF, Garfield JW. Isoniazid induction of antinuclear antibodies. A prospective study. Ann Intern Med 1978; 88:650.</a></li><li><a class="nounderline abstract_t">Gordon MM, Porter DR, Capell HA. Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. Ann Rheum Dis 1999; 58:288.</a></li><li><a class="nounderline abstract_t">Moulis G, Béné J, Sommet A, et al. Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. Lupus 2012; 21:885.</a></li><li><a class="nounderline abstract_t">de Jong HJ, Tervaert JW, Saldi SR, et al. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum 2011; 41:373.</a></li><li><a class="nounderline abstract_t">De Jong HJI, van Staa TP, Lalmohamed A, et al. Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. Ann Rheum Dis 2017; 76:1723.</a></li><li><a class="nounderline abstract_t">Pérez-De-Lis M, Retamozo S, Flores-Chávez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 2017; 16:1255.</a></li><li><a class="nounderline abstract_t">Grönhagen CM, Fored CM, Linder M, et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 2012; 167:296.</a></li><li><a class="nounderline abstract_t">Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43:2383.</a></li><li><a class="nounderline abstract_t">De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7:R545.</a></li><li><a class="nounderline abstract_t">Moulis G, Sommet A, Lapeyre-Mestre M, et al. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology (Oxford) 2014; 53:1864.</a></li><li><a class="nounderline abstract_t">Jose A, Cramer AK, Davar K, Gutierrez G. A case of drug-induced lupus erythematosus secondary to trimethoprim/sulfamethoxazole presenting with pleural effusions and pericardial tamponade. Lupus 2017; 26:316.</a></li><li><a class="nounderline abstract_t">Mahmood SB, Abou Zahr Z. Systemic lupus erythematosus triggered by trimethoprim-sulfamethoxazole. Scand J Rheumatol 2020; 49:507.</a></li><li><a class="nounderline abstract_t">Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361:211.</a></li><li><a class="nounderline abstract_t">Raschi E, Antonazzo IC, Poluzzi E, De Ponti F. Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list? Ann Rheum Dis 2021; 80:e120.</a></li><li><a class="nounderline abstract_t">Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992; 90:165.</a></li><li><a class="nounderline abstract_t">Love LA. New environmental agents associated with lupus-like disorders. Lupus 1994; 3:467.</a></li><li><a class="nounderline abstract_t">De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48:1015.</a></li><li><a class="nounderline abstract_t">Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006; 18:96.</a></li><li><a class="nounderline abstract_t">Mor A, Pillinger MH, Wortmann RL, Mitnick HJ. Drug-induced arthritic and connective tissue disorders. Semin Arthritis Rheum 2008; 38:249.</a></li><li><a class="nounderline abstract_t">Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359:579.</a></li><li><a class="nounderline abstract_t">Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43:1431.</a></li><li><a class="nounderline abstract_t">Berning SE, Iseman MD. Rifamycin-induced lupus syndrome. Lancet 1997; 349:1521.</a></li><li><a class="nounderline abstract_t">Laversuch CJ, Collins DA, Charles PJ, Bourke BE. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease. Br J Rheumatol 1995; 34:435.</a></li><li><a class="nounderline abstract_t">Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol 2001; 137:1196.</a></li><li><a class="nounderline abstract_t">Sheikhzadeh A, Schäfer U, Schnabel A. Drug-induced lupus erythematosus by amiodarone. Arch Intern Med 2002; 162:834.</a></li><li><a class="nounderline abstract_t">Spiera RF, Berman RS, Werner AJ, Spiera H. Ticlopidine-induced lupus: a report of 4 cases. Arch Intern Med 2002; 162:2240.</a></li><li><a class="nounderline abstract_t">Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31:818.</a></li><li><a class="nounderline abstract_t">Shapiro KS, Pinn VW, Harrington JT, Levey AS. Immune complex glomerulonephritis in hydralazine-induced SLE. Am J Kidney Dis 1984; 3:270.</a></li><li><a class="nounderline abstract_t">Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. QJM 1995; 88:775.</a></li><li><a class="nounderline abstract_t">Cemil BC, Atas H, Canpolat F, et al. Infliximab-induced discoid lupus erythematosus. Lupus 2013; 22:515.</a></li><li><a class="nounderline abstract_t">Yoshimasu T, Hiroi A, Uede K, Furukawa F. Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol 2001; 11:54.</a></li><li><a class="nounderline abstract_t">Thybaud-Lambay V, Decloitre F, Courtois YA. Role of the uvr gene in the SOS function inducing activity of two tryptophan pyrolysis products, Trp-P-1 and Trp-P-2, in Escherichia coli K12. Mutat Res 1986; 173:177.</a></li><li><a class="nounderline abstract_t">Totoritis MC, Tan EM, McNally EM, Rubin RL. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl J Med 1988; 318:1431.</a></li><li><a class="nounderline abstract_t">Burlingame RW, Rubin RL. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 1991; 88:680.</a></li><li><a class="nounderline abstract_t">Rubin RL. Drug-induced lupus. Expert Opin Drug Saf 2015; 14:361.</a></li><li><a class="nounderline abstract_t">McKinnon RA, Nebert DW. Possible role of cytochromes P450 in lupus erythematosus and related disorders. Lupus 1994; 3:473.</a></li><li><a class="nounderline abstract_t">Gough A, Chapman S, Wagstaff K, et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312:169.</a></li><li><a class="nounderline abstract_t">Elkayam O, Levartovsky D, Brautbar C, et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 1998; 105:484.</a></li><li><a class="nounderline abstract_t">Lawson TM, Amos N, Bulgen D, Williams BD. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2001; 40:329.</a></li><li><a class="nounderline abstract_t">Margolis DJ, Hoffstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 2007; 157:540.</a></li><li><a class="nounderline abstract_t">Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus. A systematic review. Dermatology 2000; 200:223.</a></li><li><a class="nounderline abstract_t">El-Hallak M, Giani T, Yeniay BS, et al. Chronic minocycline-induced autoimmunity in children. J Pediatr 2008; 153:314.</a></li><li><a class="nounderline abstract_t">Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005; 1051:559.</a></li><li><a class="nounderline abstract_t">De Rycke L, Baeten D, Kruithof E, et al. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005; 14:931.</a></li><li><a class="nounderline abstract_t">Atzeni F, Sarzi-Puttini P. Autoantibody production in patients treated with anti-TNF-alpha. Expert Rev Clin Immunol 2008; 4:275.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242.</a></li><li><a class="nounderline abstract_t">Keiserman B, Ronchetti MR, Monticielo OA, et al. Concomitance of IgM and IgG anti-dsDNA Antibodies Does Not Appear to Associate to Active Lupus Nephritis. Open Rheumatol J 2013; 7:101.</a></li><li><a class="nounderline abstract_t">Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus 2010; 19:1107.</a></li><li><a class="nounderline abstract_t">Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103:49.</a></li><li><a class="nounderline abstract_t">Pretel M, Marquès L, España A. Drug-induced lupus erythematosus. Actas Dermosifiliogr 2014; 105:18.</a></li><li><a class="nounderline abstract_t">He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol 2018; 30:490.</a></li><li><a class="nounderline abstract_t">Shovman O, Tamar S, Amital H, et al. Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature. Clin Rheumatol 2018; 37:563.</a></li><li><a class="nounderline abstract_t">Michaelis TC, Sontheimer RD, Lowe GC. An update in drug-induced subacute cutaneous lupus erythematosus. Dermatol Online J 2017; 23.</a></li><li><a class="nounderline abstract_t">Sandholdt LH, Laurinaviciene R, Bygum A. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2014; 170:342.</a></li><li><a class="nounderline abstract_t">Pinard J, Patel M, Granter SR, et al. Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib. J Cutan Med Surg 2018; 22:341.</a></li><li><a class="nounderline abstract_t">Callen JP. Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognized. J Am Acad Dermatol 2001; 45:315.</a></li><li><a class="nounderline abstract_t">Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139:45.</a></li><li><a class="nounderline abstract_t">Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007; 21:17.</a></li><li><a class="nounderline abstract_t">Mayor-Ibarguren A, Roldán-Puchalt MC, Gómez-Fernández C, et al. Subacute Cutaneous Lupus Erythematosus Induced by Mitotane. JAMA Dermatol 2016; 152:109.</a></li><li><a class="nounderline abstract_t">Lee HY, Pang SM. Subacute cutaneous lupus erythematosus after immunotherapy for renal-cell carcinoma: the case for interferon-alpha. Clin Exp Dermatol 2010; 35:491.</a></li><li><a class="nounderline abstract_t">Liu RC, Sebaratnam DF, Jackett L, et al. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J Dermatol 2018; 59:e152.</a></li><li><a class="nounderline abstract_t">Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009; 18:935.</a></li><li><a class="nounderline abstract_t">Shao K, McGettigan S, Elenitsas R, Chu EY. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy. J Cutan Pathol 2018; 45:74.</a></li><li><a class="nounderline abstract_t">Wang LL, Patel G, Chiesa-Fuxench ZC, et al. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy. JAMA Dermatol 2018; 154:1057.</a></li><li><a class="nounderline abstract_t">Bonaci-Nikolic B, Nikolic MM, Andrejevic S, et al. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 2005; 7:R1072.</a></li><li><a class="nounderline abstract_t">Yung RL, Johnson KJ, Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest 1995; 73:746.</a></li><li class="breakAll">Merola JF. Lupus-like syndromes related to drugs. In: Lupus erythematosus: Clinical evaluation and treatment, Schur PH, Massarotti E (Eds), Springer, New York. in press.</li><li><a class="nounderline abstract_t">Rubin RL, Burlingame RW, Arnott JE, et al. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus. J Immunol 1995; 154:2483.</a></li><li><a class="nounderline abstract_t">De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus 2006; 15:762.</a></li><li><a class="nounderline abstract_t">Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64:403.</a></li><li><a class="nounderline abstract_t">Lowe GC, Henderson CL, Grau RH, et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2011; 164:465.</a></li><li><a class="nounderline abstract_t">Marzano AV, Lazzari R, Polloni I, et al. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol 2011; 165:335.</a></li><li><a class="nounderline abstract_t">Miller FW, Hess EV, Clauw DJ, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000; 43:243.</a></li><li><a class="nounderline abstract_t">Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009; 301:99.</a></li><li><a class="nounderline abstract_t">Hillesheim PB, Bahrami S, Jeffy BG, Callen JP. Tissue eosinophilia: not an indicator of drug-induced subacute cutaneous lupus erythematosus. Arch Dermatol 2012; 148:190.</a></li><li><a class="nounderline abstract_t">Nässberger L, Johansson AC, Björck S, Sjöholm AG. Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment. J Intern Med 1991; 229:261.</a></li><li><a class="nounderline abstract_t">Cambridge G, Wallace H, Bernstein RM, Leaker B. Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994; 33:109.</a></li><li><a class="nounderline abstract_t">Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 2003; 12:651.</a></li><li class="breakAll">Mongey A-B, Hess EV. Drug-induced disease. In: Systemic Lupus Erythematosus, Fifth edition, Lahita RG, Tsokos G, Buyon J, Koike T (Eds), Academic Press, London 2011. p.599-627.</li><li><a class="nounderline abstract_t">Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 2012; 11:321.</a></li><li><a class="nounderline abstract_t">Varada S, Gottlieb AB, Merola JF, et al. Treatment of coexistent psoriasis and lupus erythematosus. J Am Acad Dermatol 2015; 72:253.</a></li></ol></div><div id="topicVersionRevision">Topic 4677 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15454126" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug-induced autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17893983" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Drug-induced lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17153847" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Drug-induced lupus: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767026" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drug-induced lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29745339" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30005854" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Drug-induced lupus: Traditional and new concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21627046" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A new epigenetic challenge: systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Drug-induced rheumatic syndromes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6432120" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The lupus syndrome induced by hydralazine: a common complication with low dose treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6103441" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2565418" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10952745" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7703999" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Role of genetic factors in drug-related autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735951" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259288" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Drug-related lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7704001" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Drugs recently associated with lupus syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2312737" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2433971" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/312047" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8318043" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30793701" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24557776" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604299" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Quinidine-induced rheumatic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074958" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Minocycline and lupuslike syndrome in acne patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20840450" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Do selected drugs increase the risk of lupus? A matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/306216" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Isoniazid induction of antinuclear antibodies. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10225813" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22333565" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868063" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association between statin use and lupus-like syndrome using spontaneous reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28684558" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28854831" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22458771" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083258" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15899041" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24899660" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27357280" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A case of drug-induced lupus erythematosus secondary to trimethoprim/sulfamethoxazole presenting with pleural effusions and pericardial tamponade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293218" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systemic lupus erythematosus triggered by trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587352" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Anti-CTLA4 antibody-induced lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31189551" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1378852" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7704003" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : New environmental agents associated with lupus-like disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12687543" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344625" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Musculoskeletal manifestations and autoimmune diseases related to new biologic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166218" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Drug-induced arthritic and connective tissue disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867114" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Drug-induced systemic lupus erythematosus associated with etanercept therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10902743" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9167470" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rifamycin-induced lupus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7788172" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559217" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11926860" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Drug-induced lupus erythematosus by amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390069" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ticlopidine-induced lupus: a report of 4 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15088316" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6229178" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Immune complex glomerulonephritis in hydralazine-induced SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542262" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Antigen specificity in hydralazine associated ANCA positive systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23554040" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Infliximab-induced discoid lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174141" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3005854" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Role of the uvr gene in the SOS function inducing activity of two tryptophan pyrolysis products, Trp-P-1 and Trp-P-2, in Escherichia coli K12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259287" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1864977" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25554102" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Drug-induced lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7704004" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Possible role of cytochromes P450 in lupus erythematosus and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8563540" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9870833" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11285382" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Minocycline-induced lupus: clinical features and response to rechallenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17596147" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10828631" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Minocycline-induced lupus. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534244" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Chronic minocycline-induced autoimmunity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16126996" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Autoimmunity and anti-TNF-alpha agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16425572" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20477056" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Autoantibody production in patients treated with anti-TNF-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632266" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24358068" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Concomitance of IgM and IgG anti-dsDNA Antibodies Does Not Appear to Associate to Active Lupus Nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693204" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Drug-induced subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3873891" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23164669" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Drug-induced lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29870500" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Drug-induced lupus erythematosus: an update on drugs and mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29063464" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329511" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : An update in drug-induced subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24547721" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Proton pump inhibitor-induced subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29307217" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11464200" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognized.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12533163" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17207162" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26444320" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438537" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Subacute cutaneous lupus erythematosus after immunotherapy for renal-cell carcinoma: the case for interferon-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28726325" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Subacute cutaneous lupus erythematosus induced by nivolumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762393" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Drug-induced lupus: an update on its dermatologic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29028121" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30027278" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16207324" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558836" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : New concepts in the pathogenesis of drug-induced lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558836" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : New concepts in the pathogenesis of drug-induced lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7868914" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17153848" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lessons for lupus from tumour necrosis factor blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297281" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21039412" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A systematic review of drug-induced subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21564069" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10693862" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Approaches for identifying and defining environmentally associated rheumatic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797892" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Drug-induced lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22004879" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Tissue eosinophilia: not an indicator of drug-induced subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1848881" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8162472" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514126" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514126" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21619949" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Therapeutic blockade of TNF in patients with SLE-promising or crazy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25486913" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment of coexistent psoriasis and lupus erythematosus.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
